Aleman, Maria M, et al. Cystamine Preparations Exhibit Anticoagulant Activity. 2015. https://doi.org/10.17615/pvby-qd21
Aleman, M., Holle, L., Stember, K., Devette, C., Monroe, D., & Wolberg, A. (2015). Cystamine Preparations Exhibit Anticoagulant Activity. https://doi.org/10.17615/pvby-qd21
Aleman, Maria M., Lori A Holle, Katherine G Stember, Christa I Devette, Dougald M Monroe, and Alisa S Wolberg. 2015. Cystamine Preparations Exhibit Anticoagulant Activity. https://doi.org/10.17615/pvby-qd21
Transglutaminases are a superfamily of isoenzymes found in cells and plasma. These enzymes catalyze the formation of ε-N-(γ-glutamyl)-lysyl crosslinks between proteins. Cystamine blocks transglutaminase activity and is used in vitro in human samples and in vivo in mice and rats in studies of coagulation, immune dysfunction, and inflammatory disease. These studies have suggested cystamine blocks fibrin crosslinking and has anti-inflammatory effects, implicating transglutaminase activity in the pathogenesis of several diseases. We measured the effects of cystamine on fibrin crosslinking, tissue factor-triggered plasma clot formation and thrombin generation, and coagulation factor enzymatic activity. At concentrations that blocked fibrin crosslinking, cystamine also inhibited plasma clot formation and reduced thrombin generation. Cystamine inhibited the amidolytic activity of coagulation factor XI and thrombin towards chromogenic substrates. These findings demonstrate that cystamine exhibits anticoagulant activity during coagulation. Given the close relationship between coagulation and inflammation, these findings suggest prior studies that used cystamine to implicate transglutaminase activity in disease pathogenesis warrant re-examination.